Replies to post #190283 on Biotech Values

[mcbio]

IMDZ > a director bought $662K(!) in an offering announced on Apr 15...the offering was expected to close on Apr 21 and raise $79M...they originally filed to raise $60M. In a collaboration last October IMDZ licensed it's GLAAS platform to Sanofi and to Medimmune in 2010. Not sure how much weight it should carry but Carl June is on the SAB.

Bruce Kovner has been buying shares of SNTA hand over fist for a few years now and at least so far that has not paid off. Maybe he will get the last laugh, who knows (count me in the skeptical camp on SNTA), but goes to show heavy insider buying is not always all it's cracked up to be.

[DewDiligence]

IMDZ, MRK collaborate on phase-2 trials of Keytruda with IMDZ’s G100 and LV305 (separately):

http://finance.yahoo.com/news/immune-design-merck-collaborate-combination-120000522.html

No cash is changing hands, evidently.

[DewDiligence]

IMDZ -8% on offering of 5.52M* shares @6.25—an 8% discount to yesterday’s close:

http://finance.yahoo.com/news/immune-design-prices-public-offering-133005667.html

*Assuming exercise of underwriter’s option.